Kidney Week

Abstract: FR-PO044

Cannabis Use and Its Association with Incidence of AKI in Advanced CKD Patients Transitioning to ESRD

Session Information

• AKI: Clinical, Outcomes, Trials - I
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

• 102 AKI: Clinical, Outcomes, and Trials

Authors

• Potukuchi, Praveen Kumar, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Praveen Kumar Potukuchi,

• Sumida, Keiichi, Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, kanagawa, Japan

Keiichi Sumida,

• Molnar, Miklos Zsolt, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Miklos Zsolt Molnar,

• Gaipov, Abduzhappar, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Abduzhappar Gaipov,

• Park, Frank, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Frank Park,

• Kaplan, Cameron M., University of Tennessee Health Science Center, Memphis, Tennessee, United States

Cameron M. Kaplan,

• Moradi, Hamid, University of California Irvine, School of Medicine, Orange, California, United States

Hamid Moradi,

• Thomas, Fridtjof, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Fridtjof Thomas,

• Gatwood, Justin, University of Tennessee Health Science Center, Memphis, Tennessee, United States

Justin Gatwood,

• Streja, Elani, Harold Simmons Center for Kidney Disease Research and Epidemiology, Orange, California, United States

Elani Streja,

• Kalantar-Zadeh, Kamyar, University of California Irvine, School of Medicine, Orange, California, United States

Kamyar Kalantar-Zadeh,

• Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States

Csaba P. Kovesdy,

Background

Cannabinoid receptors are expressed in the kidneys and their stimulation may have both harmful and beneficial effects. Synthetic cannabinoid use is associated with acute kidney injury (AKI) in case reports, but the effects of cannabis use on the incidence of AKI in patients with advanced CKD is unknown.

Methods

We examined 2,416 US veterans who transitioned to dialysis during 2007-2014 and had undergone urine toxicology tests up to one year prior to dialysis, and had serial serum creatinine levels measured within 7 days after the test. We compared patients whose toxicology tests were positive for cannabis alone (primary exposure group, PEG, N=76) with those whose tests were negative (negative control group, NCG, N=1,138). AKI was defined according to KDIGO creatinine–based criteria. We examined the association of cannabis use with AKI using logistic regression adjusted for sociodemographics, comorbidities, medications, and vital signs.

Results

The mean (SD) age of the cohort was 60.6 (9.3) years; 97% were male, 46.7 % were African American and 76.4% were diabetic. AKI occurred in 58.6% of the cohort. Cannabis use was not associated with the odds of AKI in crude or in multivariable adjusted models (multivariable adjusted odds ratios (and 95%CI) in PEG vs. NCG: 0.75 (0.45-1.24); Figure 1).

Conclusion

Cannabis use in advanced CKD patients is not associated with the incidence of AKI.

Funding

• NIDDK Support